-
British Medical Journal Feb 1960
Topics: Oxytocics
PubMed: 13837695
DOI: 10.1136/bmj.1.5170.413 -
Contraception, Fertilite, Sexualite... Mar 1998
Review
Topics: Drug Costs; Humans; Labor, Induced; Oxytocics; Prostaglandins
PubMed: 9592966
DOI: No ID Found -
British Journal of Obstetrics and... Jan 1988Recent claims that routine active management of the third stage of labour increases rather than decreases maternal and neonatal morbidity have prompted us to conduct a... (Clinical Trial)
Clinical Trial Review
Recent claims that routine active management of the third stage of labour increases rather than decreases maternal and neonatal morbidity have prompted us to conduct a systematic review of the relevant controlled trials. In this paper we have analysed data derived from a total of nine published reports of controlled trials in which an oxytocic drug was compared with either a placebo or no routine prophylactic. Oxytocic drugs used routinely appear to reduce the risk of postpartum haemorrhage by about 40% (typical odds ratio 0.57, 95% confidence interval 0.44-0.73) implying that for every 22 women given such an oxytocic, one postpartum haemorrhage could be prevented. The available data are insufficient to assess the possible effects of this policy on the incidence of retained placenta, hypertension and other possible adverse effects.
Topics: Clinical Trials as Topic; Female; Humans; Labor Stage, Third; Labor, Obstetric; Oxytocics; Postpartum Hemorrhage; Pregnancy
PubMed: 3277663
DOI: 10.1111/j.1471-0528.1988.tb06475.x -
MCN. the American Journal of Maternal... 2020
Topics: Adult; Dystocia; Female; Humans; Oxytocics; Oxytocin; Pregnancy
PubMed: 33074919
DOI: 10.1097/NMC.0000000000000659 -
BJOG : An International Journal of... Apr 2003The perfect tocolytic agent, which is completely safe for both the mother and fetus and, which will inhibit uterine contractions and stop preterm labour in every case... (Review)
Review
The perfect tocolytic agent, which is completely safe for both the mother and fetus and, which will inhibit uterine contractions and stop preterm labour in every case does not exist and the search continues. Recently, research into a new group of tocolytic agents (the oxytocic antagonists) has led to the introduction of a new licensed drug, atosiban. Since the early 1950s, modifications of the oxytocin molecule have resulted in many analogues and antagonists, though initially none emerged as potentially useful drugs. Further modifications resulted in full uterotonic antagonism in animal models before an analogue was found that inhibited vasopressin-stimulated uterine contractions in non-pregnant healthy women. In vitro and animal models suggested the molecule was fully antagonistic, although it was found to be only partially agonistic in women. Further developments led to two modified oxytocin molecules with higher receptor affinity for human myometrium, both of which lacked agonism in humans. The analogue, atosiban, was found to be more potent and so was chosen for clinical evaluation in dysmenorrhoea and preterm labour. The first clinical reports were open label, observational pilot studies. Randomised, double-blind, phase II placebo-controlled studies followed showing that atosiban was significantly more effective than placebo with very few side effects. Dose-response studies and phase III studies in which study or placebo groups could use alternative tocolytic agents also suggested that atosiban was an effective tocolytic agent with very few adverse events. The recent worldwide comparative study of atosiban versus different beta-agonists represents the largest and most strictly controlled study of tocolytics ever published. Atosiban was found to be at least as effective as the beta-agonists as a tocolytic agent, but significantly less likely to result in maternal cardiovascular side effects or the need to discontinue therapy as a result of unacceptable side effects.
Topics: Clinical Trials, Phase II as Topic; Double-Blind Method; Drug Design; Female; Humans; Obstetric Labor, Premature; Oxytocics; Pregnancy; Randomized Controlled Trials as Topic; Risk Factors; Tocolytic Agents; Vasotocin
PubMed: 12763125
DOI: No ID Found -
Best Practice & Research. Clinical... Aug 2020Augmentation of labour aims at improving the efficiency of uterine contractions in order to reduce maternal and foetal adverse outcomes associated with prolonged labour.... (Review)
Review
Augmentation of labour aims at improving the efficiency of uterine contractions in order to reduce maternal and foetal adverse outcomes associated with prolonged labour. This review covers the current best practice for different methods of augmentation of labour, namely, artificial rupture of membranes and oxytocin infusion as a prevention of, or therapy for, prolonged labour. The review highlights essential practice points and identifies knowledge gaps for future research in this important area of clinical obstetric practice.
Topics: Female; Humans; Labor, Induced; Oxytocics; Oxytocin; Pregnancy; Prenatal Care; Time Factors; Uterine Contraction
PubMed: 32360367
DOI: 10.1016/j.bpobgyn.2020.03.011 -
American Journal of Obstetrics and... Oct 1965
Review
Topics: Abortion, Induced; Abortion, Therapeutic; Drug Therapy; Dystocia; Female; Humans; Labor, Induced; Labor, Obstetric; Oxytocics; Pharmacology; Pregnancy
PubMed: 14337382
DOI: 10.1016/0002-9378(65)90074-8 -
Canadian Medical Association Journal Mar 1961
Topics: Dimenhydrinate; Female; Humans; Obstetrics; Oxytocics; Pregnancy
PubMed: 13783459
DOI: No ID Found -
The Nebraska Medical Journal Aug 1980
Topics: Female; Humans; Labor, Induced; Oxytocics; Pregnancy
PubMed: 7402403
DOI: No ID Found -
The Practitioner Jan 1968
Topics: Animals; Female; Humans; Oxytocics; Oxytocin; Rabbits; Rats
PubMed: 5636261
DOI: No ID Found